### S4 Table. Baseline characteristics of patients with stage IV adenocarcinoma in 2015

|                                | Total       | Non-survivor | Survivor | p-value |
|--------------------------------|-------------|--------------|----------|---------|
| **No. of patients**            | 348         | 310          | 38       |         |
| **Male sex**                   | 212 (60.9)  | 192 (61.9)   | 20 (52.6)| 0.267   |
| **Age (yr)**                   | 69.0 (59.0-75.0) | 70.0 (59.8-76.0) | 62.0 (56.0-72.3) | 0.058   |
| **Ever-smoker**                | 181 (52.0)  | 163 (52.6)   | 18 (47.4)| 0.518   |
| **BMI (kg/m²)**                | 21.0 (20.2-21.7) | 20.9 (20.0-21.6) | 22.1 (19.7-24.3) | 0.300   |
| **Symptoms**                   | 342         | 305          | 37       |         |
| Asymptomatic                   | 22 (6.4)    | 19 (6.2)     | 3 (8.1)  | 0.673   |
| Cough                          | 120 (35.1)  | 109 (35.7)   | 11 (29.7)| 0.447   |
| Sputum                         | 53 (15.5)   | 47 (15.4)    | 6 (16.2) | 0.919   |
| Dyspnea                        | 93 (27.2)   | 85 (27.9)    | 8 (21.6) | 0.403   |
| Hoarseness                     | 9 (2.6)     | 7 (2.3)      | 2 (5.4)  | 0.271   |
| Hemoptysis                     | 10 (2.9)    | 9 (3.0)      | 1 (2.7)  | 0.925   |
| Weight loss                    | 26 (7.6)    | 24 (7.9)     | 2 (5.4)  | 0.583   |
| Pain                           | 92 (26.9)   | 87 (28.5)    | 5 (13.5) | 0.049   |
| **Performance status**         | 255         | 225          | 30       |         |
| 0-1                            | 216 (84.7)  | 188 (83.6)   | 28 (93.3)| 0.162   |
| 2-4                            | 39 (15.3)   | 37 (16.4)    | 2 (6.7)  |         |
| **EGFR**                       | 118/304 (38.8) | 101/270 (37.4) | 17/34 (50.0) | 0.328   |
| **ALK**                        | 19/233 (8.2)| 12/209 (5.7)| 7/24 (29.2)| <0.001  |

Values are presented as the number (%) or median (interquartile range). ALK, anaplastic lymphoma kinase; BMI, body mass index; EGFR, epidermal growth factor receptor.